{"id":"NCT02770716","sponsor":"Mallinckrodt","briefTitle":"Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1","officialTitle":"A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-13","primaryCompletion":"2019-07-24","completion":"2019-07-24","firstPosted":"2016-05-12","resultsPosted":"2022-08-18","lastUpdate":"2022-11-29"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatorenal Syndrome"],"interventions":[{"type":"DRUG","name":"Terlipressin","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":["Matching Placebo"]}],"arms":[{"label":"Terlipressin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is to treat adult patients with hepatorenal syndrome (HRS) Type 1.\n\nOut of every three participants, two will receive terlipressin and one will receive placebo.\n\nAssignments will be made randomly.","primaryOutcome":{"measure":"Percentage of Participants With Verified HRS Reversal","timeFrame":"within 15 Days","effectByArm":[{"arm":"Terlipressin","deltaMin":29.1,"sd":null},{"arm":"Placebo","deltaMin":15.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":64,"countries":["United States","Canada"]},"refs":{"pmids":["40704461","37302573","37143199","36633470","33657294"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":142,"n":200},"commonTop":["Abdominal pain","Nausea","Diarrhoea","Dyspnoea","Hepatic encephalopathy"]}}